[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$f65-g5LTUgHIk8dGZIHhGe2pKpxnfW0g-O4HGxk3yxcs":3,"$f2q6peK4AkPXxIOh3DN-wAt4R6ZqJXgLG7TlmTSf91wQ":8,"$fG8xGE2vaVHM0tbFr79Sj1htC91KwOhxrR2sA9AKEkHY":55,"$fO2IBa8xniVmKgflB754WpoMh1mFx4ueDXaqQqPUDzzU":59},{"code":4,"msg":5,"message":6,"data":6,"success":7},401,"认证失败，无法访问系统资源",null,false,{"code":9,"msg":10,"message":6,"data":11,"success":54},200,"操作成功",{"id":12,"specialistId":13,"specialistAssistants":14,"profilePhoto":15,"specialistName":16,"hospital":17,"department":18,"postsTitle":19,"materialTotal":20,"videoTotal":21,"isConcern":7,"title":22,"coverVertical":23,"coverAcross":24,"content":25,"description":26,"views":27,"likes":21,"isThumbsUp":7,"isCollection":7,"collections":21,"createTime":28,"seoTitle":22,"seoKeywords":29,"seoDescription":30,"shelvesTime":31,"version":32,"menus":33,"menuId":35,"type":42,"quality":53,"commentCount":21,"isComment":42},53443,870348,[],"https://cdn.haohuanjiao.com/learnMaterial/ystApp//fkIPBigdRB0BZukwpdQeSzMKecCQjNwG.png","张然","天津市肿瘤医院空港医院","肿瘤科","住院医师",4,0,"乳腺癌新辅助治疗用药安全指南：TCb方案与免疫治疗全景详解","","https://ystcdn.venuertc.com/venue/AI/a471ca32-0d47-4194-9152-52d6fc5219af.jpg","\u003Cdiv id=\"material_title\" class=\"tcbl_guide-title\">\n  乳腺癌新辅助治疗用药安全指南：TCb方案与免疫治疗全景详解\n\u003C/div>\n\u003Cdiv class=\"tcbl_guide-intro\">\n  说到肿瘤新辅助治疗，不少朋友都听过TCb方案和免疫治疗这两个名字。其实，这两类药物是当前非常重要的抗癌工具，但药物用法和注意事项非常讲究。本指南将从7个关键角度彻底讲清楚这些药品的核心使用细节、禁忌和常见风险，帮助大家真正做到用药安全、效果最大化。\n\u003C/div>\n\n\u003C!-- 01 剂型解析：TCb方案与免疫治疗用药形式大观 -->\n\u003Cdiv class=\"tcbl_guide-section\">\n  \u003Cdiv class=\"tcbl_guide-section-head\" style=\"background:linear-gradient(90deg,#f6f9fb 70%,#e1e9f2 100%);\">\n    \u003Cspan>💊\u003C/span> 剂型解析：TCb方案与免疫治疗用药形式大观\n  \u003C/div>\n  \u003Cdiv class=\"tcbl_guide-section-body\">\n    \u003Cul class=\"tcbl_guide-list\">\n      \u003Cli>\n        \u003Cb>多西他赛（Paclitaxel/Docetaxel）\u003C/b>：主要剂型为注射用液体制剂，通常以静脉输注方式给药。规格常见为20mg、80mg、100mg等。\n      \u003C/li>\n      \u003Cli>\n        \u003Cb>卡铂（Carboplatin）\u003C/b>：同样为静脉注射剂，需根据体表面积及肾功能进行剂量调整。一般以溶液形式给药，规格多为50mL、100mL。\n      \u003C/li>\n      \u003Cli>\n        \u003Cb>免疫检查点抑制剂（以帕博利珠单抗[Keytruda]为例）\u003C/b>：为浓缩液体制剂，用前需用氯化钠注射液稀释后静脉滴注，规格常为100mg/4mL。\n      \u003C/li>\n    \u003C/ul>\n    \u003Cdiv class=\"tcbl_guide-tips\">\n      正确做法：所有上述药物均应由专业医务人员操作，切勿自行购药或擅自调整给药剂型。\n    \u003C/div>\n    \u003Cdiv class=\"tcbl_guide-case\">\n      临床上，一位中年女性采用标准TCb方案联合PD-1抑制剂时，严格遵循静脉输注要求，未出现注射过程异常，有效保障了治疗安全。\n    \u003C/div>\n  \u003C/div>\n\u003C/div>\n\n\u003C!-- 02 用法用量要精准：怎么用才对 -->\n\u003Cdiv class=\"tcbl_guide-section\">\n  \u003Cdiv class=\"tcbl_guide-section-head\" style=\"background:linear-gradient(90deg,#f6f9fb 70%,#e7ebe5 100%);\">\n    \u003Cspan>⏳\u003C/span> 用法用量要精准：怎么用才对\n  \u003C/div>\n  \u003Cdiv class=\"tcbl_guide-section-body\">\n    \u003Cul class=\"tcbl_guide-list\">\n      \u003Cli>\n        \u003Cb>多西他赛\u003C/b>：常见推荐剂量为每平方米体表面积75mg，3周静脉滴注一次，每次输注时间约1小时，须避免漏针渗漏。\n      \u003C/li>\n      \u003Cli>\n        \u003Cb>卡铂\u003C/b>：剂量一般根据AUC（Area Under Curve，曲线下面积）来决定，通常AUC5-6，每3周一次。用药前需依据肾功能检测结果做个体化调整。\n      \u003C/li>\n      \u003Cli>\n        \u003Cb>免疫检查点抑制剂\u003C/b>：如帕博利珠单抗，多为每3周静脉滴注一次，每次用量一般为200mg。首次用药前后建议增加监护。\n      \u003C/li>\n    \u003C/ul>\n    \u003Cdiv class=\"tcbl_guide-tips\">\n      正确做法：所有剂量由医生根据信息核查和体检结果专属定制，请勿参考他人标准擅自换药或加减量。\n    \u003C/div>\n    \u003Cdiv class=\"tcbl_guide-case\">\n      一位患者在多西他赛输注日曾自行缩短输液时间，导致术后短期内出现不适，经医护人员调整按标准流程给药后未再出现问题。这说明标准给药流程安全系数高。\n    \u003C/div>\n  \u003C/div>\n\u003C/div>\n\n\u003C!-- 03 作用机制速览：为什么联合用药 -->\n\u003Cdiv class=\"tcbl_guide-section\">\n  \u003Cdiv class=\"tcbl_guide-section-head\" style=\"background:linear-gradient(90deg,#f6f9fb 70%,#ecf5e8 100%);\">\n    \u003Cspan>🧬\u003C/span> 作用机制速览：为什么联合用药\n  \u003C/div>\n  \u003Cdiv class=\"tcbl_guide-section-body\">\n    \u003Cul class=\"tcbl_guide-list\">\n      \u003Cli>\n        \u003Cb>多西他赛\u003C/b>：为紫杉烷类抗肿瘤药，通过抑制细胞微管蛋白聚合，阻断肿瘤细胞分裂周期，使细胞无法繁殖。\n      \u003C/li>\n      \u003Cli>\n        \u003Cb>卡铂\u003C/b>：属于铂类药，能与DNA结合，干扰肿瘤细胞基因复制，直接阻止肿瘤细胞增殖。\n      \u003C/li>\n      \u003Cli>\n        \u003Cb>免疫检查点抑制剂\u003C/b>：如帕博利珠单抗，为PD-1抗体，可以解除肿瘤细胞对免疫系统的抑制，让人体T细胞更有效地识别并清除肿瘤细胞（Sharma & Allison, 2015）。\n      \u003C/li>\n    \u003C/ul>\n    \u003Cdiv class=\"tcbl_guide-tips\">\n      联合使用主要是希望通过多途径干预，提高药物清除恶性细胞的效率。\n    \u003C/div>\n  \u003C/div>\n\u003C/div>\n\n\u003C!-- 04 药物禁忌和高危人群，千万别疏忽 -->\n\u003Cdiv class=\"tcbl_guide-section\">\n  \u003Cdiv class=\"tcbl_guide-section-head\" style=\"background:linear-gradient(90deg,#f6f9fb 70%,#f8eced 100%);\">\n    \u003Cspan>🚫\u003C/span> 药物禁忌和高危人群，千万别疏忽\n  \u003C/div>\n  \u003Cdiv class=\"tcbl_guide-section-body\">\n    \u003Cul class=\"tcbl_guide-list\">\n      \u003Cli>\n        \u003Cb>多西他赛禁忌\u003C/b>：严重肝功能损害者禁用，对多西他赛或同类药物过敏者禁用。\n      \u003C/li>\n      \u003Cli>\n        \u003Cb>卡铂禁忌\u003C/b>：血小板减少严重、未控制感染者禁用，有严重肾损伤病史者不得用。\n      \u003C/li>\n      \u003Cli>\n        \u003Cb>PD-1抑制剂禁忌\u003C/b>：对药品成分过敏、高度活动性自身免疫病患者禁用。\n      \u003C/li>\n    \u003C/ul>\n    \u003Cdiv class=\"tcbl_guide-tips\">\n      特别提醒：孕妇、哺乳期女性及青少年患者采用TCb方案及免疫治疗时，必须有严格医学指导，不建议随意启用。\n    \u003C/div>\n  \u003C/div>\n\u003C/div>\n\n\u003C!-- 05 药物相互作用：哪些组合要小心 -->\n\u003Cdiv class=\"tcbl_guide-section\">\n  \u003Cdiv class=\"tcbl_guide-section-head\" style=\"background:linear-gradient(90deg,#f6f9fb 70%,#fff6e7 100%);\">\n    \u003Cspan>⚠️\u003C/span> 药物相互作用：哪些组合要小心\n  \u003C/div>\n  \u003Cdiv class=\"tcbl_guide-section-body\">\n    \u003Cul class=\"tcbl_guide-list\">\n      \u003Cli>\n        \u003Cb>多西他赛\u003C/b>：不能与酮康唑、伊曲康唑等强CYP3A4酶抑制剂同用，否则会显著提高多西他赛血药浓度，增加毒性风险（Gurpide et al., 2018）。\n      \u003C/li>\n      \u003Cli>\n        \u003Cb>卡铂\u003C/b>：与氨基糖苷类抗生素同用时肾损害风险提升；与其他免疫抑制剂、骨髓抑制药合用，会增强骨髓抑制副作用。\n      \u003C/li>\n      \u003Cli>\n        \u003Cb>免疫检查点抑制剂\u003C/b>：受全身性激素、其他免疫抑制药影响效果，部分药物可能削弱免疫激活作用，所以联合其他药物需权衡风险和获益。\n      \u003C/li>\n    \u003C/ul>\n    \u003Cdiv class=\"tcbl_guide-tips\">\n      需要注意：如现正使用抗真菌药、某些抗生素以及长期糖皮质激素治疗，应提前如实告知医生，由专业人员评估能否安全联合。\n    \u003C/div>\n  \u003C/div>\n\u003C/div>\n\n\u003C!-- 06 常见不良反应和应对方式：用药效果好，副作用要防 -->\n\u003Cdiv class=\"tcbl_guide-section\">\n  \u003Cdiv class=\"tcbl_guide-section-head\" style=\"background:linear-gradient(90deg,#f6f9fb 70%,#f4e8fa 100%);\">\n    \u003Cspan>⚕️\u003C/span> 常见不良反应和应对方式：用药效果好，副作用要防\n  \u003C/div>\n  \u003Cdiv class=\"tcbl_guide-section-body\">\n    \u003Cul class=\"tcbl_guide-list\">\n      \u003Cli>\n        \u003Cb>多西他赛\u003C/b>：80%以上患者可能出现白细胞减少或中性粒细胞减少，部分患者（10%以内）有消化道反应、关节肌肉疼痛。\n      \u003C/li>\n      \u003Cli>\n        \u003Cb>卡铂\u003C/b>：常见不良反应为恶心、呕吐和骨髓抑制（主要表现在低白细胞和血小板），肾功能异常在高危人群中更明显。\n      \u003C/li>\n      \u003Cli>\n        \u003Cb>PD-1类免疫检查点抑制剂\u003C/b>：最值得注意的是免疫相关异常反应，可能导致皮疹、肝功能异常、甲状腺功能改变等（Postow et al., 2018）。\n      \u003C/li>\n    \u003C/ul>\n    \u003Cdiv class=\"tcbl_guide-tips\">\n      正确做法：出现持续发热、异常出血、呼吸急促、剧烈皮疹等情况时，要及时到医院检查处理，不能自行暂停或换药。\n    \u003C/div>\n    \u003Cdiv class=\"tcbl_guide-case\">\n      有位患者接受TCb联合PD-1治疗后短期内出现中性粒细胞骤降，在医务人员定期监测和辅助用药下顺利度过危险期并未影响后续持续用药。\n    \u003C/div>\n    \u003Cdiv class=\"tcbl_guide-tips\">\n      正确做法：每次化疗及免疫治疗期间，都要做血常规、生化及心/肝/肾功能的监测，监测后由医生判断是否可继续下个疗程。\n    \u003C/div>\n  \u003C/div>\n\u003C/div>\n\n\u003C!-- 07 储存和运输：药品质量护航保障 -->\n\u003Cdiv class=\"tcbl_guide-section\">\n  \u003Cdiv class=\"tcbl_guide-section-head\" style=\"background:linear-gradient(90deg,#f6f9fb 70%,#e2f5f8 100%);\">\n    \u003Cspan>🎁\u003C/span> 储存和运输：药品质量护航保障\n  \u003C/div>\n  \u003Cdiv class=\"tcbl_guide-section-body\">\n    \u003Cul class=\"tcbl_guide-list\">\n      \u003Cli>\n        \u003Cb>多西他赛\u003C/b>：原包装密闭避光储存，通常要求置于2~8℃冰箱内，勿冷冻。\n      \u003C/li>\n      \u003Cli>\n        \u003Cb>卡铂\u003C/b>：溶液需低温避光保存，用药当天现配。未稀释的原液可在2~8℃保存。\n      \u003C/li>\n      \u003Cli>\n        \u003Cb>免疫检查点抑制剂\u003C/b>：需密闭低温储存，不宜强烈震荡或长时间放置室温环境。\n      \u003C/li>\n    \u003C/ul>\n    \u003Cdiv class=\"tcbl_guide-tips\">\n      特别提醒：药品运输需全程冷链保证，开封或稀释后若未按时用完须丢弃，严禁自行带药回家保存使用。\n    \u003C/div>\n  \u003C/div>\n\u003C/div>\n\n\u003C!-- 08 忘记用药/用药过量，一旦发生怎么办 -->\n\u003Cdiv class=\"tcbl_guide-section\">\n  \u003Cdiv class=\"tcbl_guide-section-head\" style=\"background:linear-gradient(90deg,#f6f9fb 70%,#e1e9f2 100%);\">\n    \u003Cspan>🕑\u003C/span> 忘记用药/用药过量，一旦发生怎么办\n  \u003C/div>\n  \u003Cdiv class=\"tcbl_guide-section-body\">\n    \u003Cul class=\"tcbl_guide-list\">\n      \u003Cli>\n        \u003Cb>忘记化疗/免疫治疗时间\u003C/b>：尽快和主治疗医生联系，按照医嘱补充疗程，切勿擅自补药或提前下次治疗。\n      \u003C/li>\n      \u003Cli>\n        \u003Cb>不慎用药过量\u003C/b>：应立即停止用药，同时入院监护，预防中毒及严重并发症，由专业医疗团队处理。\n      \u003C/li>\n    \u003C/ul>\n    \u003Cdiv class=\"tcbl_guide-tips\">\n      需要注意：因为这些药物多为医务人员输注，漏服和过量不常见，但务必按医生预约准时，绝不可自行补药。\n    \u003C/div>\n  \u003C/div>\n\u003C/div>\n\n\u003C!-- 09 特殊人群用药调整：老年⼈、肾⽓功能差者、孕妇要注意 -->\n\u003Cdiv class=\"tcbl_guide-section\">\n  \u003Cdiv class=\"tcbl_guide-section-head\" style=\"background:linear-gradient(90deg,#f6f9fb 70%,#fff7f0 100%);\">\n    \u003Cspan>👵\u003C/span> 特殊人群用药调整：老年⼈、肾⽓功能差者、孕妇要注意\n  \u003C/div>\n  \u003Cdiv class=\"tcbl_guide-section-body\">\n    \u003Cul class=\"tcbl_guide-list\">\n      \u003Cli>\n        \u003Cb>老年患者\u003C/b>：身体储备功能低，通常需减少多西他赛、卡铂剂量，并严格强化肾功能及血液系统监测。\n      \u003C/li>\n      \u003Cli>\n        \u003Cb>肝肾功能异常者\u003C/b>：多西他赛、卡铂剂量需减量，根据肝酶及血清肌酐水平动态调整用药方案。\n      \u003C/li>\n      \u003Cli>\n        \u003Cb>孕妇和哺乳期妇女\u003C/b>：多数指南建议避免使用，明确需要治疗时要权衡胎儿和母体风险，由专科评估后制订个体化方案。\n      \u003C/li>\n    \u003C/ul>\n    \u003Cdiv class=\"tcbl_guide-tips\">\n      特别提醒：所有特殊群体用药都必须由医学专科把关，切不可自己模仿或参考他人经验自行决定治疗方式。\n    \u003C/div>\n  \u003C/div>\n\u003C/div>\n\n\u003C!-- 10 结语：安全用药，责任在心 -->\n\u003Cdiv class=\"tcbl_guide-summary\" style=\"background:linear-gradient(90deg,#f9fafb 70%,#e6f0fc 100%);\">\n  TCb方案与免疫治疗的药物联合为肿瘤治疗带来了新的希望，也对用药安全和细节把控提出更高要求。需始终记住：严格按医嘱使用合适剂型和剂量、避免自行组合非医嘱药物、不自行储存、不盲目更改时间或剂量，是保障治疗效果与身体安全的关键。如果遇到不适症状或新副作用，应第一时间联系主治医生，获得科学专业的处理建议。每一次用药都是对生命的认真负责。\n\u003C/div>\n\n\u003C!-- 11 文献参考 -->\n\u003Cdiv class=\"tcbl_guide-section\">\n  \u003Cdiv class=\"tcbl_guide-section-head\" style=\"background:linear-gradient(90deg,#f6f9fb 70%,#eaeaea 100%);\">\n    \u003Cspan>📚\u003C/span> 参考文献\n  \u003C/div>\n  \u003Cdiv class=\"tcbl_guide-section-body\">\n    \u003Col class=\"tcbl_guide-ref\">\n      \u003Cli>Sharma, P. & Allison, J. P. (2015). The future of immune checkpoint therapy. Science, 348(6230), 56–61. doi:10.1126/science.aaa8172\u003C/li>\n      \u003Cli>Postow, M. A., Sidlow, R., & Hellmann, M. D. (2018). Immune-related adverse events associated with immune checkpoint blockade. The New England Journal of Medicine, 378(2), 158-168. doi:10.1056/NEJMra1703481\u003C/li>\n      \u003Cli>Gurpide, A., Zoccoli, M. A., & Di Leo, A. (2018). Drug interactions with taxanes in oncology. European Journal of Pharmacology, 834, 127–138. doi:10.1016/j.ejphar.2018.07.025\u003C/li>\n    \u003C/ol>\n  \u003C/div>\n\u003C/div>\n\u003Cstyle>\n.tcbl_guide-title {\n  font-size: 2.6em;\n  font-weight: bold;\n  background: linear-gradient(90deg,#f7faff 80%,#ecf1f6 100%);\n  border-radius: 16px;\n  text-align: center;\n  padding: 36px 8px 18px 8px;\n  color: #2c3e50;\n  margin: 0 0 24px 0;\n  letter-spacing: 2px;\n}\n\n.tcbl_guide-intro {\n  font-size: 1.22em;\n  color: #486182;\n  background: #f3f7fa;\n  border-left: 6px solid #8eafdf;\n  border-radius: 0 18px 18px 0;\n  padding: 18px 30px 14px 30px;\n  margin: 0 0 32px 0;\n  line-height: 1.8;\n}\n\n.tcbl_guide-section {\n  margin: 0 0 24px 0;\n  box-shadow: 0 2px 4px rgba(212,227,248,0.08);\n  border-radius: 18px;\n  overflow: hidden;\n  background: #fafcff;\n}\n\n.tcbl_guide-section-head {\n  font-size: 1.25em;\n  font-weight: bold;\n  padding: 18px 24px 14px 28px;\n  color: #5b6277;\n  border-bottom: 1px solid #e9f1ff;\n  display: flex;\n  align-items: center;\n  gap: 14px;\n}\n\n.tcbl_guide-section-body {\n  padding: 24px 34px;\n  color: #34495e;\n  font-size: 1.07em;\n}\n\n.tcbl_guide-list {\n  margin: 0 0 10px 0;\n  padding: 0 0 0 28px;\n  line-height: 2.0;\n}\n.tcbl_guide-list li b {\n  color: #377bb6;\n  font-weight: 600;\n}\n\n.tcbl_guide-case {\n  margin: 22px 0 0 0;\n  background: #eaf4fe;\n  border-left: 5px solid #71afd2;\n  border-radius: 0 8px 8px 0;\n  padding: 10px 18px 10px 18px;\n  color: #287095;\n  font-style: italic;\n  font-size: 1.01em;\n}\n.tcbl_guide-tips {\n  margin: 18px 0 2px 0;\n  background: #f7faed;\n  border-left: 5px solid #9bbb7b;\n  padding: 8px 18px 9px 18px;\n  border-radius: 0 8px 8px 0;\n  color: #324d1b;\n  font-size: 1.01em;\n}\n\n.tcbl_guide-summary {\n  font-size: 1.15em;\n  color: #47667d;\n  background: linear-gradient(90deg, #f6fafd 70%, #ecf2f9 100%);\n  padding: 28px 30px;\n  border-radius: 14px;\n  margin: 28px 0 38px 0;\n  line-height: 1.8;\n}\n\n.tcbl_guide-ref {\n  font-size: 1.04em;\n  margin: 8px 0 0 21px;\n  padding: 0;\n  color: #515774;\n  line-height: 2.0;\n}\n\u003C/style>\n","\u003Cdiv id=\"material_title\" class=\"tcbl_guide-title\">\n  乳腺癌新辅助治疗用药安全指南：TCb方案与免疫治疗全景详解\n\u003C/div>\n\u003Cdiv class",522,"2025-07-28 14:38:43","乳腺癌, TCb方案, 免疫治疗, 新辅助治疗, 药物用法, 药物禁忌, 常见副作用, 用药安全","了解TCb方案与免疫治疗的用药安全指南，提供关键药物的使用细节与注意事项，为癌症患者与护理人员提供详尽信息与权威指导。","2025-07-29 22:36:00",2,[34],{"menuId":35,"menuName":36,"parentId":21,"orderNum":32,"path":37,"component":38,"isFrame":39,"isCache":40,"menuType":41,"visible":42,"status":21,"createDept":6,"remark":23,"createTime":43,"children":44,"columnImage":45,"columnLogo":46,"uncheckedLogo":6,"checkedLogo":6,"isHot":42,"isHome":21,"forceLogin":21,"color":47,"seoTitle":48,"seoKeywords":49,"seoDescription":50,"contentNum":6,"promotionalPoster":51,"menuFrame":7,"innerLink":7,"parentView":7,"routeName":52,"routerPath":37,"componentInfo":38},"1986713082609147906","健康科普","article","/article.html","1","0","T",1,"2025-11-07 16:31:25",[],"https://ystcdn.venuertc.com/venue/undefined/2026-01-24-18:08:49/d4291d16-ed1c-48dd-84c8-ec1f85980b75.png","https://ystcdn.venuertc.com/venue/undefined/2026-01-24-18:08:52/6fe64094-9416-442c-a66d-032fb292666a.png","#c8e6ca","健康科普助力健康中国2030:共享健康知识新理念","健康科普, 健康中国, 科普知识, 健康家庭, 性健康, 营养健康, 运动健康, 科普宣传","探索健康科普在健康中国行动中的重要角色,了解最新的健康科普创新大赛、动漫及短视频,传播健康知识,助力全民健康。","https://ystcdn.venuertc.com/venue/undefined/2026-01-24-18:08:56/bd33f471-6c54-4d1b-a364-b06973dbc144.png","Article","癌症肿瘤",true,{"code":9,"msg":10,"message":6,"data":56,"success":54},{"pageNo":42,"pageSize":57,"result":58,"totalSize":21},10,[],{"code":9,"msg":10,"message":6,"data":60,"success":54},{"authors":61,"appraiseDimensionScoresVos":62},[],[]]